Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueInventory Average

RedHill Biopharma (RDHL) Return on Capital Employed (2016 - 2023)

Historic Return on Capital Employed for RedHill Biopharma (RDHL) over the last 10 years, with Q2 2023 value amounting to 2.34%.

  • RedHill Biopharma's Return on Capital Employed rose 876700.0% to 2.34% in Q2 2023 from the same period last year, while for Jun 2023 it was 2.34%, marking a year-over-year increase of 876700.0%. This contributed to the annual value of 8708581.64% for FY2024, which is 87085814700.0% up from last year.
  • As of Q2 2023, RedHill Biopharma's Return on Capital Employed stood at 2.34%, which was up 876700.0% from 1.09% recorded in Q4 2022.
  • RedHill Biopharma's Return on Capital Employed's 5-year high stood at 1.09% during Q4 2022, with a 5-year trough of 90.01% in Q2 2022.
  • Its 5-year average for Return on Capital Employed is 9.83%, with a median of 0.58% in 2021.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first tumbled by -906000bps in 2022, then skyrocketed by 876700bps in 2023.
  • RedHill Biopharma's Return on Capital Employed (Quarter) stood at 0.93% in 2019, then plummeted by -32bps to 0.63% in 2020, then crashed by -226bps to 0.79% in 2021, then soared by 237bps to 1.09% in 2022, then crashed by -316bps to 2.34% in 2023.
  • Its last three reported values are 2.34% in Q2 2023, 1.09% for Q4 2022, and 90.01% during Q2 2022.